A Glimpse Into The Expert Outlook On Autolus Therapeutics Through 5 Analysts
Analysts’ ratings for Autolus Therapeutics (NASDAQ:AUTL) over the last quarter vary from bullish to bearish, as provided by…
Autolus Therapeutics Presents Additional Data Analysis Of Pivotal Phase 2 Felix Study Of obe-cel For Adult r/r B-all In An Oral Presentation At ASCO
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes40% patients are in ongoing remission without subsequent stem cell transplant
Crude Oil Gains 1%; GameStop Shares Plunge
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 50 points on…
Why Cracker Barrel Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Shares of Cracker Barrel Old Country Store, Inc. (NASDAQ:CBRL) fell sharply during Friday’s session after the company reduced…
Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Dow Jones gaining around 0.1% on Friday. Shares of Despegar.com, Corp. (NYSE:DESP)…
Autolus Therapeutics Announces Abstract For Longer-Term Follow-Up And Additional Data Analysis Of Pivotal Phase 2 FELIX Study Of obe-cel For Adult r/r B-ALL Selected For An Oral Presentation At ASCO
Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for longer-term follow-up and additional
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers Ontrak (NASDAQ:OTRK) shares increased by 18.7% to $0.45 during Thursday’s after-market session. The company’s market cap stands…
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
BioNTech SE (NASDAQ:BNTX, ", BioNTech", )))), a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, and Autolus Therapeutics plc (NASDAQ:AUTL, ",
CORRECTION FDA Accepts Autolus Therapeutics’ Marketing Application For Obecabtagene Autoleucel For Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia, With Target Action Date Of November 16, 2024
Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the U.S.
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers Cyclo Therapeutics (NASDAQ:CYTH) stock rose 34.1% to $2.2 during Wednesday’s after-market session. The market value of their…